Cycle Duration 48 weeks Repeatable Yes Suggested Bloodwork (4 tests) DEXA body composition scan When: Baseline Why: Baseline fat mass and lean mass measurement HbA1c When: Baseline Why: Baseline glycemic control assessment CMP (Comprehensive Metabolic Panel) When: Baseline Why: Baseline liver and kidney function DEXA body composition scan When: 24 weeks Why: Monitor fat mass and lean mass changes Key Considerations Investigational drug: not approved by any regulatory agency Monoclonal antibody requiring IV infusion: not available for self-administration Common side effects include muscle spasms, diarrhea, and acne Unlock dosing protocols Free access to research-backed dosing information for all peptides
Studies show an average weight loss of 5-10% of body weight with Ozempic, used alongside lifestyle changes
Clients often choose NAD++ during demanding work periods, frequent travel, intensive training, or when they want broader recovery and nutritional support
The HR for the primary outcome was 0.82 (95% CI, 0.730.93)
The glucagon receptor component of retatrutide's mechanism is of particular interest for liver health, as glucagon signalling is thought to play a role in hepatic fat metabolism, though the precise mechanisms in humans remain under investigation
Theriogenology 206, 161169
